Modality
Cell Therapy
MOA
TNFi
Target
SHP2
Pathway
PD-1/PD-L1
RSVParkinson'sThymoma
Development Pipeline
Preclinical
~Dec 2016
→ ~Mar 2018
Phase 1
~Jun 2018
→ ~Sep 2019
Phase 2
~Dec 2019
→ ~Mar 2021
Phase 3
~Jun 2021
→ ~Sep 2022
NDA/BLA
~Dec 2022
→ ~Mar 2024
Approved
Jun 2024
→ Mar 2029
ApprovedCurrent
NCT06071844
302 pts·Thymoma
2024-06→2029-03·Terminated
302 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2029-03-133.0y awayPh3 Readout· Thymoma
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Approved
Termina…
Catalysts
Ph3 Readout
2029-03-13 · 3.0y away
Thymoma
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06071844 | Approved | Thymoma | Terminated | 302 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D |